BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

International Wex Technologies (WXI): US$5.1 Million Convertible Debenture


10/19/2005 5:11:23 PM

International Wex Technologies Inc. (TSX: WXI) ("Wex" or the "Company") is pleased to announce that its wholly owned subsidiary, Wex Medical Limited, has agreed in principle to issue unsecured convertible debentures in the aggregate principal amount of US$5.1 million (the "Debentures") to major Asian financial institutions. This issue is non-brokered and no commissions or finders' fee will be payable. The Debentures will have a term of 5 years and will carry an annual coupon of 5.5%, payable semi annually. The Debentures will be guaranteed by Wex. The Debentures will be convertible at the option of the holders at any time until maturity into common shares of Wex at a conversion price of CDN$5.00 per share. As an incentive for early conversion, Wex will pay, in common shares of Wex at a price of CDN$5.00 per share, a bonus amount of 4% of the face value of any of the Debentures converted within the first year. Wex may at its option force conversion of the Debentures provided the daily closing price of common shares in Wex equals or exceeds CDN$7.50 per share for 10 consecutive trading days. The issuance of the Debentures will be subject to the approval of the Toronto Stock Exchange. Closing is expected to occur within 30 days.

Read at CCNMatthews

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES